Odonate Therapeutics Inc (OQ:ODT)

Business Focus: Pharmaceuticals

Sector:  Healthcare Industry:  Pharmaceuticals
See Regulatory Filings on SEC
Company Contact
Address: 4747 Executive Dr Ste 510
SAN DIEGO CA 92121-3100
Tel: N/A
Website: https://www.odonate.com
IR: See website
Key People
Kevin C. Tang
Chairman of the Board, Chief Executive Officer
Jeff L. Vacirca
Vice Chairman of the Board
Michael S. Hearne
Chief Financial Officer
John G. Lemkey
Chief Operating Officer
Joseph P. O'Connell
Chief Medical Officer
Business Overview
Odonate Therapeutics, Inc., formerly Odonate Therapeutics, LLC, is a pharmaceutical company. The Company is engaged in the development of therapeutics to improve and extend the lives of patients with cancer. It is focused on the development of tesetaxel, a novel chemotherapy agent. It has completed Phase-II studies in patients with metastatic breast cancer (MBC). The Company's tesetaxel can be administered orally with a low pill burden and dosing regimen. Taxanes destroy cancer cells by preventing them from entering mitosis and thereby leading to apoptosis (cell death).
Financial Overview
For the six months ended 30 June 2019, Odonate Therapeutics Inc revenues was not reported. Net loss increased 58% to $57.3M. Higher net loss reflects Research and development increase of 64% to $48M (expense), Stock-based Compensation in R&D increase from $2.2M to $5.1M (expense), Stock-based Compensation in SGA increase from $397K to $842K (expense).
Employees: 117 as of Dec 31, 2018
Reporting Currency: U.S. Dollars
Enterprise value: $712.69M as of Jun 30, 2019
Annual revenue (TTM): $0.00M as of Jun 30, 2019
EBITDA (TTM): -$112.04M as of Jun 30, 2019
Net annual income (TTM): -$110.04M as of Jun 30, 2019
Free cash flow (TTM): -$89.06M as of Jun 30, 2019
Net Debt Last Fiscal Year: N/A
Shares outstanding: 32,187,490 as of Jul 10, 2019
TTM: Trailing Twelve Months
EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization